Novo Nordisk A/S $NVO Stock Position Decreased by Bank of Montreal Can

Bank of Montreal Can cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 57.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,057,418 shares of the company’s stock after selling 1,417,882 shares during the period. Bank of Montreal Can’s holdings in Novo Nordisk A/S were worth $58,676,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. SG Americas Securities LLC lifted its stake in Novo Nordisk A/S by 2,101.5% during the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock valued at $132,242,000 after buying an additional 2,274,925 shares in the last quarter. DAVENPORT & Co LLC increased its position in shares of Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after acquiring an additional 935,468 shares in the last quarter. Sustainable Growth Advisers LP raised its holdings in shares of Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after acquiring an additional 649,390 shares during the period. Baird Financial Group Inc. lifted its position in shares of Novo Nordisk A/S by 42.6% in the 2nd quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock valued at $101,920,000 after acquiring an additional 441,034 shares in the last quarter. Finally, Holocene Advisors LP purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,745,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 2.0%

Novo Nordisk A/S stock opened at $38.04 on Friday. Novo Nordisk A/S has a 12 month low of $35.85 and a 12 month high of $82.57. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a market cap of $169.83 billion, a P/E ratio of 10.96 and a beta of 0.73. The company’s fifty day simple moving average is $50.43 and its 200-day simple moving average is $51.92.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. HSBC reiterated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research note on Tuesday. Four analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $49.93.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Zacks upgraded Novo Nordisk from “strong sell” to “hold,” a modest vote that may limit further downside from some retail/quant sellers. Read More.
• Positive Sentiment: Novo entered a WHO Foundation partnership focused on cardio‑renal‑metabolic diseases and committed funding for obesity/diabetes efforts in low‑ and middle‑income countries — a reputational and long‑term access play that supports the company’s global public‑health positioning. Read More.
• Neutral Sentiment: Novo Holdings published 2025 annual results showing income and investment returns; while the report is routine, its figures are being viewed through the lens of Novo Nordisk’s share‑price swing. Read More.
• Neutral Sentiment: India’s regulator warned drugmakers about direct or surrogate advertising for weight‑loss drugs, a policy development that adds regulatory complexity across a large and fast‑growing market but is industry‑wide rather than Novo‑specific. Read More.
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide, triggering immediate regulatory risk and heightened compliance scrutiny that can hurt investor confidence and valuation. Read More.
• Negative Sentiment: Regulatory news sparked sharp market reaction and legal attention: a class‑action/investor probe (Pomerantz) was announced and some articles report a very steep intraday drop tied to the FDA news, increasing the chance of litigation and reputational/financial fallout. Read More.
• Negative Sentiment: Analysts have reacted: TD Cowen and others trimmed ratings/targets, and coverage notes the hit to Novo Holdings’ controlling‑shareholder asset value — both amplify selling pressure. Read More.
• Negative Sentiment: Competitive pressure from Eli Lilly (big investments and programs to expand GLP‑1 access) is a strategic negative for Novo’s long‑term market share and pricing power in GLP‑1s. Investors should factor stronger Lilly initiatives into longer‑term growth forecasts. Read More.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.